Antibody-dependent cellular cytotoxicity pathway component (ADCC pathway component)

The term **antibody-dependent cellular cytotoxicity pathway component** does not refer to a single molecule or protein target but rather a set of cellular and molecular participants involved in the **antibody-dependent cellular cytotoxicity (ADCC) pathway**. ADCC is an immune effector mechanism in which antibodies bind to antigens on the surface of a target cell, after which immune effector cells such as natural killer (NK) cells, macrophages, and neutrophils recognize the bound antibodies' Fc regions using their Fc receptors (e.g., FcγRIIIa/CD16A). Upon engagement, these effector cells are activated to release cytotoxic molecules (e.g., perforin, granzymes) and/or induce apoptosis, leading to target cell lysis[1][2][3][4][5]. Key **components** of the pathway include: - Fc gamma receptors (FcγRs, e.g., CD16A) on effector cells - Immunoglobulin classes (primarily IgG, but also IgA, IgE in some contexts) - Effector cell subsets (NK cells, macrophages, neutrophils, monocytes, eosinophils) - Cytotoxic effectors (perforin, granzyme, FasL) - Target cell antigens and surface characteristics No single molecule called "antibody-dependent cellular cytotoxicity pathway component" exists; the concept refers to the collection of proteins, cells, and antibodies comprising the ADCC immune mechanism. Thus, it is not a druggable target in the conventional sense, but rather a biological process or axis that can be therapeutically engaged, manipulated, or enhanced (e.g., using monoclonal antibodies in cancer immunotherapy)[3][4][5].

Other names

Antibody-dependent cell-mediated cytotoxicity pathway component